Normal skin
Melan-A (Dako Omnis)
IVD
For In Vitro Diagnostic Use.
- Monoclonal Mouse Anti-Human
No data to display
This product is not available for purchase by the general public.
Product Details
Features
- Optimized staining performance of both high and low-expression structures
- Crisp and clear staining with no background
- Optimal laboratory efficiency with ready-to-use antibodies on Dako Omnis family of instruments
- Consistent, uniform staining with excellent morphology enabled by dynamic gap staining technology on the Dako Omnis family of instruments
- Defined, tested, and approved staining performance for all FLEX RTU antibodies through collaboration with leading international pathology experts
Specifications
| Application |
|
| Clone |
|
| Code Number |
|
| Form/Configuration |
|
| Immunogen |
|
| Isotype |
|
| Reagent Provided |
|
| Solutions |
|
| Species |
|
| Specificity |
|
| Volume |
|
Literature
- Catalogs
-
Atlas of Controls
The Atlas of Controls illustrates the staining performance of each antibody in the FLEX Ready-to-Use system.
- Catalogs
- English
- 31 Jul 2026
- 37.96 MB
- Technical Overviews
Support
- Instructions for Use
-
Featured References
- Product Description References
-
1.Chen, Y.-T.; Stockert, E.; Jungbluth, A.; Tsang, S.; Coplan, K. A.; Scanlan, M. J.; Old, L. J. Serological analysis of Melan-A (MART-1), a melanocyte-specific protein homogeneously expressed in human melanomas. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 5915–5919. DOI: 10.1073/pnas.93.12.5915.
2.Coulie, P. G.; Brichard, V.; Van Pel, A.; Wölfel, T.; Schneider, J.; Traversari, C.; Mattei, S.; De Plaen, E.; Lurquin, C.; Szikora, J.-P.; Renauld, J.-C.; Boon, T. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med. 1994, 180, 35–42. DOI: 10.1084/jem.180.1.35.
4.Yazdanfard, N. W.; Mikkelsen, L. H.; Behrendt, N.; Fuglsang, K.; Blaakær, J.; Hölmich, L. R.; Frøding, L. P.; Munch-Petersen, H. F.; Heegaard, S. Vaginal melanoma in Denmark from 1980 to 2018: A population-based study based on genetic profile and survival. Gynecol. Oncol. 2022, 165, 53–59. DOI: 10.1016/j.ygyno.2022.01.028.
5.Zhou, J. J.; Huang, Y.; Zhang, X.; Cheng, Y.; Tang, L.; Ma, X. Eyes absent gene (EYA1) is a pathogenic driver and a therapeutic target for melanoma. Oncotarget 2017, 8, 105081–105092. DOI: 10.18632/oncotarget.21352.
6.Fässler, M.; Diem, S.; Mangana, J.; Hasan Ali, O.; Berner, F.; Bomze, D.; Ring, S.; Niederer, R.; Gil Cruz, C. del C.; Pérez Shibayama, C. I.; Krolik, M.; Siano, M.; Joerger, M.; Recher, M.; Risch, L.; Güsewell, S.; Risch, M.; Speiser, D. E.; Ludewig, B.; Levesque, M. P.; Dummer, R.; Flatz, L. Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients. J. Immunother. Cancer 2019, 7, 50. DOI: 10.1186/s40425-019-0523-2.
7.Mikkelsen, L. H.; Maag, E.; Andersen, M. K.; Kruhøffer, M.; Larsen, A.-C.; Melchior, L. C.; Toft, P. B.; von Buchwald, C.; Wadt, K.; Heegaard, S. The molecular profile of mucosal melanoma. Melanoma Res. 2020, 30, 533–542. DOI: 10.1097/CMR.0000000000000686.
8.Funakoshi, A.; Honda, T.; Ito, T.; Tokura, Y. Cholecystokinin receptor antagonist suppresses melanoma growth by inducing apoptosis of tumor cells. JID Innov. 2022, 2, 100153. DOI: 10.1016/j.xjidi.2022.100153.
Related Products
Promotions